The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Dr. Jonathan Trent on FDA Approval of Trabectedin for Soft Tissue Sarcomas

Jonathan Trent, MD
Published Online: 6:37 PM, Thu November 5, 2015


Jonathan C. Trent, MD, professor of Medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the FDA approval of trabectedin for patients with soft tissue sarcomas.


Trabectedin was approved in the United States after a promising phase III study that consisted of 518 patients who had previously been treated with anthracycline. Trabectedin was approved for use in patients with soft tissue sarcoma, including liposarcoma and leiomyosarcoma subtypes, on October 23, 2015.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.